The purpose of this study is to assess the long-term symptomatic response (Visit 2 \[Week 1\] to Visit 14/Week 66 \[End of Study {EOS}\]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month \[PP1M\] and 3-month \[PP3M\] formulations).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
93
Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
University Teaching Hospital of Butare(CHUB)
Butare, Rwanda
Kibuye Referral Hospital
Kibuye, Rwanda
CARAES Ndera Neuro-Psychiatric Hospital
Kigali, Rwanda
University Teaching Hospital of Kigali
Kigali, Rwanda
Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Mean Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
Rwamagana Provincial Hospital
Rwamagana, Rwanda
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \[very dissatisfied\] to 5 \[very satisfied\]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Number of Participants with Treatment-emergent Adverse Events
An adverse event is any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events are adverse events with onset after the initiation of treatment in observation phase and separately for initiation of paliperidone palmitate (PP) in Lead-in phase or that are a consequence of a pre-existing condition that has worsened after each treatment phase starts.
Time frame: Up to Week 66
Number of Participants with Abnormalities in Clinical Laboratory Measures
Number of participants with abnormalities in clinical laboratory measures (including serum chemistry, hematology and urinalysis) will be reported.
Time frame: Up to Week 66
Number of Participants with Abnormalities in Vital Signs
Number of participants with abnormalities in vital signs (temperature \[oral\], pulse/heart rate, and blood pressure) will be reported.
Time frame: Up to Week 66
Number of Participants with Abnormalities in Electrocardiogram (ECG)
Number of participants with abnormalities in ECG will be reported.
Time frame: Up to Week 66
Number of Participants with Abnormalities in Physical Examination
Number of participants with abnormalities in physical examination (including body weight, waist circumference, and height) will be reported.
Time frame: Up to Week 66
Number of Participants With Pregnancy Outcome as a Safety Measure
Number of participants with pregnancy outcome will be reported.
Time frame: Up to Week 66
Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS) Score
C-SSRS is an approved and standardized scale for the assessment of the severity of suicidality, through clinical interview. The maximum score assigned for each participant will be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity. Number of participants with suicidal ideation and behavior will be reported.
Time frame: Visit 12 (Week 46) to Visit 14 (Week 66 [EOS])